Traders Sell Shares of Gilead Sciences Inc. (GILD) on Strength (GILD)
Traders sold shares of Gilead Sciences Inc. (NASDAQ:GILD) on strength during trading on Friday. $99.32 million flowed into the stock on the tick-up and $127.18 million flowed out of the stock on the tick-down, for a money net flow of $27.86 million out of the stock. Of all companies tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.41 for the day and closed at $81.00
A number of analysts recently issued reports on GILD shares. Piper Jaffray Cos. reiterated an “overweight” rating on shares of Gilead Sciences in a research note on Tuesday, August 16th. RBC Capital Markets set a $105.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, August 11th. Jefferies Group reiterated a “hold” rating and set a $93.00 price objective on shares of Gilead Sciences in a research note on Monday, August 1st. Argus lowered Gilead Sciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $88.00 to $81.00 in a research note on Friday, July 29th. Finally, Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Ten research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $107.37.
The company has a market cap of $106.89 billion and a P/E ratio of 7.11. The firm has a 50 day moving average of $82.88 and a 200-day moving average of $87.37.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.02 by $0.06. During the same quarter in the prior year, the business posted $3.15 EPS. The company earned $7.78 billion during the quarter, compared to analysts’ expectations of $7.80 billion. The company’s revenue was down 5.7% on a year-over-year basis. Analysts forecast that Gilead Sciences Inc. will post $11.78 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Friday, September 16th will be given a $0.47 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.32%.
In other Gilead Sciences news, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $79.81, for a total transaction of $159,620.00. Following the completion of the transaction, the executive vice president now owns 64,122 shares in the company, valued at $5,117,576.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John C. Martin sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $80.50, for a total value of $8,050,000.00. Following the transaction, the insider now owns 4,119,727 shares of the company’s stock, valued at approximately $331,638,023.50. The disclosure for this sale can be found here.
Several hedge funds and institutional investors have made changes to their positions in GILD. Adirondack Trust Co. raised its position in shares of Gilead Sciences by 6.2% in the fourth quarter. Adirondack Trust Co. now owns 12,500 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 729 shares during the period. Sfmg LLC raised its position in shares of Gilead Sciences by 5.2% in the fourth quarter. Sfmg LLC now owns 10,619 shares of the biopharmaceutical company’s stock valued at $1,075,000 after buying an additional 522 shares during the period. Pekin Singer Strauss Asset Management IL raised its position in shares of Gilead Sciences by 3.3% in the fourth quarter. Pekin Singer Strauss Asset Management IL now owns 12,681 shares of the biopharmaceutical company’s stock valued at $1,283,000 after buying an additional 400 shares during the period. Azimuth Capital Management LLC raised its position in shares of Gilead Sciences by 195.0% in the fourth quarter. Azimuth Capital Management LLC now owns 12,894 shares of the biopharmaceutical company’s stock valued at $1,305,000 after buying an additional 8,523 shares during the period. Finally, Platinum Investment Management Ltd. acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $1,315,000.
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.